Gamco Investors INC. ET AL Sells 500 Shares of Masimo Co. (NASDAQ:MASI)

Gamco Investors INC. ET AL trimmed its position in Masimo Co. (NASDAQ:MASI) by 0.6% in the second quarter, according to its most recent filing with the SEC. The fund owned 84,500 shares of the medical equipment provider’s stock after selling 500 shares during the period. Gamco Investors INC. ET AL’s holdings in Masimo were worth $13,904,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. Financial Gravity Asset Management Inc. bought a new position in shares of Masimo in the 2nd quarter valued at $451,000. National Bank of Canada FI bought a new position in Masimo during the 2nd quarter worth $29,000. Caisse DE Depot ET Placement DU Quebec bought a new position in Masimo during the 1st quarter worth $37,000. Achmea Investment Management B.V. bought a new position in Masimo during the 2nd quarter worth $39,000. Finally, Trivant Custom Portfolio Group LLC bought a new position in Masimo during the 1st quarter worth $55,000. 85.96% of the stock is currently owned by institutional investors.

Masimo Stock Performance

Shares of MASI opened at $94.69 on Tuesday. The company has a debt-to-equity ratio of 0.71, a current ratio of 2.14 and a quick ratio of 1.13. The stock has a 50-day moving average of $86.83 and a 200-day moving average of $122.29. The company has a market cap of $5.00 billion, a PE ratio of 57.74 and a beta of 0.88. Masimo Co. has a one year low of $75.22 and a one year high of $198.00.

Masimo (NASDAQ:MASI) last issued its earnings results on Tuesday, November 7th. The medical equipment provider reported $0.63 EPS for the quarter, beating the consensus estimate of $0.59 by $0.04. The company had revenue of $478.90 million during the quarter, compared to the consensus estimate of $498.73 million. Masimo had a return on equity of 14.18% and a net margin of 4.19%. The firm’s revenue for the quarter was down 12.8% compared to the same quarter last year. During the same period last year, the business posted $1.00 EPS. On average, equities research analysts predict that Masimo Co. will post 2.93 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on MASI shares. Raymond James lowered Masimo from an “outperform” rating to a “market perform” rating in a research report on Wednesday, November 8th. Needham & Company LLC lowered their target price on Masimo from $136.00 to $86.00 and set a “buy” rating for the company in a research report on Wednesday, November 8th. StockNews.com downgraded Masimo from a “hold” rating to a “sell” rating in a report on Thursday, November 16th. Finally, Wells Fargo & Company decreased their price target on Masimo from $110.00 to $81.00 and set an “equal weight” rating for the company in a report on Wednesday, November 8th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $122.00.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and O3 regional oximetry.